Related Experiment Video

Updated: May 30, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

MicroRNAs and Alzheimer's Disease Mouse Models: Current Insights and Future Research Avenues

Charlotte Delay1, Sébastien S Hébert

  • 1Axe Neurosciences, Centre de Recherche du CHUQ (CHUL), Québec, QC, Canada G1V4G2.

International Journal of Alzheimer'S Disease
|August 10, 2011
PubMed

Insights

MicroRNAs (miRNAs) are implicated in Alzheimer's disease (AD) neurodegeneration. Studying miRNA changes in AD mouse models can reveal cause-consequence relationships and aid in developing diagnostics.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Alzheimer's disease (AD) involves amyloid and tau pathologies causing neurodegeneration.
  • MicroRNAs (miRNAs), small noncoding RNAs, regulate genes crucial for neuronal function and survival.
  • Emerging evidence suggests miRNAs play a role in both genetic and sporadic forms of AD.

Purpose of the Study:

  • To investigate the role of microRNAs (miRNAs) as contributing factors in Alzheimer's disease (AD) pathology.
  • To explore the cause-consequence relationship between miRNA dysfunction and AD pathogenesis using mouse models.
  • To validate miRNA targets in vivo and study miRNA-dependent gene pathways in AD.

Main Methods:

  • Utilizing AD mouse models to study changes in microRNA expression.
  • Investigating the in vivo validation of miRNA targets within these models.
  • Analyzing specific miRNA-dependent gene pathways implicated in AD.

Main Results:

  • AD mouse models offer a platform to study miRNA involvement in neurodegeneration.
  • These models facilitate the in vivo validation of miRNA targets.
  • Mouse models enable the exploration of specific miRNA-driven pathways in AD.

Conclusions:

  • MicroRNA (miRNA) dysfunction is potentially a significant factor in Alzheimer's disease (AD) pathogenesis.
  • AD mouse models are valuable tools for understanding miRNA roles and validating therapeutic targets.
  • Mouse models hold promise for developing novel miRNA-based diagnostics for AD.

More Related Videos

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...